Abstract:Objective: To study the effects of epicatechin on inflammatory cytokines in lipopolysaccharide (LPS)-induced macrophage model and its mechanism. Method: The in vitro inflammation model was established by stimulating RAW 264.7 cells with LPS (1 mg·L-1) for 24 h. The toxic effect of macrophages were detected by 3-(4, 5-Dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay. The content of nitricoxide (NO) was assayed by Griess reagent.Enzyme linked immunosorbent assay(ELISA) were used to assay the content of inflammatory mediators, such as tumor necrosis factor-α (TNF-α), interleukin-1(IL-1) and interleukin-6 (IL-6) in cell supernatant. The protein expressions of nitric oxide synthase (iNOS) and the related proteins of mitogen-activated protein kinase (MAPK) pathway were tested by Western blot. Result: The cell viability was not significantly affected by epicatechin at 100 μmol·L-1. Compared with control group, LPS could significantly induce RAW 264.7 cells to secrete inflammatory mediators, like NO, TNF-α, IL-1 and IL-6(P<0.01). Compared with model group, 25-100 μmol·L-1of epicatechin in LPS-induced RAW 264.7 cells greatly inhibited the release of inflammatory mediators, such as NO, TNF-α, IL-1 and IL-6 (P<0.05, P<0.01), and inhibit the expressions of iNOS, and the protein expression of p38MAPK, ERK1/2 and JNK in a dose dependent manner. Conclusion: Epicatechin can inhibit LPS-induced inflammatory response in RAW 264.7 cells, and its anti-inflammatory effect may be related to reduction of inflammatory cytokines, like NO, TNF-α, IL-1 and IL-6, inhibition of the gene expression of iNOS and phosphorylation of p38MAPK, ERK1/2 and JNK.